Regardless of PD-L1 status, bispecific immune checkpoint inhibitors improve survival in patients with gastric cancer.

Published Date: 10 Apr 2024

Patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal cancer showed improved progression-free survival and overall survival when treated with chemotherapy and the PD-1/CTLA-4 bispecific antibody cadonilimab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot